All Stories

  1. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database

    Article • Diabetes Obesity and Metabolism, December 2017, Wiley

    Elisheva LEW

  2. Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain

    Article • Journal of Medical Economics, March 2017, Taylor & Francis

    Elisheva LEW